Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;23(4):843-852.
doi: 10.1111/codi.15464. Epub 2020 Dec 15.

Does oncological outcome differ between restorative and nonrestorative low anterior resection in patients with primary rectal cancer?

Collaborators, Affiliations

Does oncological outcome differ between restorative and nonrestorative low anterior resection in patients with primary rectal cancer?

Sapho X Roodbeen et al. Colorectal Dis. 2021 Apr.

Abstract

Aim: Nonrestorative low anterior resection (n-rLAR) (also known as low Hartmann's) is performed for rectal cancer when a poor functional outcome is anticipated or there have been problems when constructing the anastomosis. Compared with restorative LAR (rLAR), little oncological outcome data are available for n-rLAR. The aim of this study was to compare oncological outcomes between rLAR and n-rLAR for primary rectal cancer.

Method: This was a nationwide cross-sectional comparative study including all elective sphincter-saving LAR procedures for nonmetastatic primary rectal cancer performed in 2011 in 71 Dutch hospitals. Oncological outcomes of patients undergoing rLAR and n-rLAR were collected in 2015; the data were evaluated using Kaplan-Meier survival analysis and the results compared using log-rank testing. Uni- and multivariable Cox regression analysis was used to evaluate the association between the type of LAR and oncological outcome measures.

Results: A total of 1197 patients were analysed, of whom 892 (75%) underwent rLAR and 305 (25%) underwent n-rLAR. The 3-year local recurrence (LR) rate was 3% after rLAR and 8% after n-rLAR (P < 0.001). The 3-year disease-free survival and overall survival rates were 77% (rLAR) vs 62% (n-rLAR) (P < 0.001) and 90% (rLAR) vs 75% (n-rLAR) (P < 0.001), respectively. In multivariable Cox analysis, n-rLAR was independently associated with a higher risk of LR (OR = 2.95) and worse overall survival (OR = 1.72).

Conclusion: This nationwide study revealed that n-rLAR for rectal cancer was associated with poorer oncological outcome than r-LAR. This is probably a noncausal relationship, and might reflect technical difficulties during low pelvic dissection in a subset of those patients, with oncological implications.

Keywords: local recurrence; low anterior resection; oncological outcome; rectal surgery.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
(A) Kaplan‐Meier survival curves of 3‐year local recurrence‐free (A) and 3‐year overall survival (B) proportion of the totale groups. n‐rLAR, nonrestorative low anterior resection; rLAR, restorative low anterior resection

Comment in

References

    1. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg. 1998;133:894–9. - PubMed
    1. Desai DC, Brennan EJ Jr, Reilly JF, Smink RD Jr. The utility of the Hartmann procedure. Am J Surg. 1998;175:152–4. - PubMed
    1. Seah DW, Ibrahim S, Tay KH. Hartmann procedure: is it still relevant today? ANZ J Surg. 2005;75:436–40. - PubMed
    1. Bujko K, Nowacki MP, Kepka L, Oledzki J, Bebenek M, Kryj M. Postoperative complications in patients irradiated pre‐operatively for rectal cancer: report of a randomised trial comparing short‐term radiotherapy vs chemoradiation. Colorectal Dis. 2005;7:410–6. - PubMed
    1. Sebag‐Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC‐CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20. - PMC - PubMed